Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.1K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

14.1K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

152
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
152
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

132
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
132
Pleiotropy01:33

Pleiotropy

31.0K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Chrono-Metabolic Approach to Mental Health: Current Perspectives on Circadian Rhythms, Gut Microbiota, and Microbial Metabolites in Mood Disorders.

Metabolites·2026
Same author

Disordered Minds, Disordered Meals: When Emotions Masquerade as Hunger in Eating Disorders-A Systematic Review.

Nutrients·2026
Same author

Risk of Head and Neck Cancer in Former Smokers by Subsite: A Multicenter Analysis From the INHANCE Consortium.

International journal of cancer·2026
Same author

Genotype-driven cerebrovascular risk across age and sex in hereditary hemorrhagic telangiectasia.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Eagle's syndrome: two approaches using VITOM 3D exoscope for an underestimated pathology.

Journal of surgical case reports·2026
Same author

Genotype-phenotype correlations and protein domain-level predictors of cerebrovascular malformations in hereditary hemorrhagic telangiectasia.

Journal of neurology·2026

Related Experiment Video

Updated: Apr 21, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

20.5K

A case-control study on proinflammatory genetic polymorphisms on sudden sensorineural hearing loss.

Gabriella Cadoni1, Eleonora Gaetani, Pasqualina M Picciotti

  • 1Department of Otorhinolaryngology, Catholic University of the Sacred Heart, Rome, Italy.

The Laryngoscope
|October 28, 2014
PubMed
Summary

Sudden sensorineural hearing loss (SSNHL) risk is linked to the Interleukin-6 (IL-6) gene 174G/G polymorphism. This finding suggests IL-6 may play a role in inner ear inflammation related to atherosclerosis.

Keywords:
E-selectinMCP-1 (CCL2)Polymorphismsinflammatory moleculesinterleukin-6 genesudden sensorineural hearing loss

More Related Videos

Isolation and Culture of Primary Marginal Cells of the Stria Vascularis from Neonatal Mice
07:58

Isolation and Culture of Primary Marginal Cells of the Stria Vascularis from Neonatal Mice

Published on: March 20, 2026

100
Cryosectioning and Immunostaining Mouse Inner Ear Tissue: From Embryonic to Adult Stages
09:09

Cryosectioning and Immunostaining Mouse Inner Ear Tissue: From Embryonic to Adult Stages

Published on: April 11, 2025

2.2K

Related Experiment Videos

Last Updated: Apr 21, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

20.5K
Isolation and Culture of Primary Marginal Cells of the Stria Vascularis from Neonatal Mice
07:58

Isolation and Culture of Primary Marginal Cells of the Stria Vascularis from Neonatal Mice

Published on: March 20, 2026

100
Cryosectioning and Immunostaining Mouse Inner Ear Tissue: From Embryonic to Adult Stages
09:09

Cryosectioning and Immunostaining Mouse Inner Ear Tissue: From Embryonic to Adult Stages

Published on: April 11, 2025

2.2K

Area of Science:

  • Otolaryngology
  • Genetics
  • Immunology

Background:

  • Sudden sensorineural hearing loss (SSNHL) is associated with inner ear vascular issues and atherosclerotic risk factors.
  • Inflammatory molecules are key in atherosclerosis, but their role in SSNHL etiology is unclear.

Purpose of the Study:

  • To investigate the role of proinflammatory genetic polymorphisms in MCP-1 (CCL2), E-selectin, and Interleukin-6 (IL-6) genes in SSNHL.
  • To evaluate the association between specific gene variants and the risk of developing SSNHL.

Main Methods:

  • Genotyping of single nucleotide polymorphisms (SNPs) in MCP-1, E-selectin, and IL-6 genes.
  • Comparison of allele and genotype frequencies between 87 SSNHL patients and 107 healthy controls.

Main Results:

  • No significant differences were found for MCP-1 and E-selectin gene polymorphisms between SSNHL patients and controls.
  • A significant association was observed for the IL-6 gene (P < .0001).

Conclusions:

  • The 174G/G polymorphism of the IL-6 gene is significantly associated with an increased risk of SSNHL.
  • Elevated IL-6 levels and the -174G/G polymorphism suggest IL-6's involvement in SSNHL pathogenesis through atherosclerotic inflammatory pathways.